Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer

7 May 2018

Abstract excerpt

PURPOSE: Triple-negative breast cancer (TNBC) is associated with worse outcomes relative to other breast cancer subtypes. Chemotherapy remains the standard-of-care systemic therapy for patients with localized or metastatic disease, with few biomarkers to guide benefit. METHODS: We will discuss recent advances in our understanding of two key biological processes in TNBC, homologous recombination (HR) DNA repair...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29736741
DOI: 10.1007/s10549-018-4807-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancerPMID 29736741Read ↗

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature ReviewSemantic proximity Read ↗

Triple-Negative Breast Cancer: Molecular Particularities Still a ChallengeSemantic proximity Read ↗

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerSemantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer.Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.Semantic proximity Read ↗

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read ↗

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.Semantic proximity Read ↗

Integrative Analysis of Homologous Recombination Repair Patterns Unveils Prognostic Signatures and Immunotherapeutic Insights in Breast CancerSemantic proximity Read ↗

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerSemantic proximity Read ↗

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.